Cumberland Pharmaceuticals (CPIX) Competitors $3.22 -0.49 (-13.21%) Closing price 04:00 PM EasternExtended Trading$3.52 +0.30 (+9.32%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CPIX vs. OMER, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Omeros (OMER), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Cumberland Pharmaceuticals vs. Its Competitors Omeros Assembly Biosciences Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Royalty Pharma Cumberland Pharmaceuticals (NASDAQ:CPIX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends. Does the media favor CPIX or OMER? In the previous week, Cumberland Pharmaceuticals had 15 more articles in the media than Omeros. MarketBeat recorded 20 mentions for Cumberland Pharmaceuticals and 5 mentions for Omeros. Omeros' average media sentiment score of 1.12 beat Cumberland Pharmaceuticals' score of -0.19 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral Omeros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in CPIX or OMER? 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 44.9% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend CPIX or OMER? Omeros has a consensus price target of $18.00, indicating a potential upside of 435.71%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omeros 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk and volatility, CPIX or OMER? Cumberland Pharmaceuticals has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Is CPIX or OMER more profitable? Omeros has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -7.98%. Cumberland Pharmaceuticals' return on equity of 6.92% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets Cumberland Pharmaceuticals-7.98% 6.92% 2.33% Omeros N/A N/A -59.68% Which has better valuation and earnings, CPIX or OMER? Cumberland Pharmaceuticals has higher revenue and earnings than Omeros. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCumberland Pharmaceuticals$37.87M1.27-$6.48M-$0.25-12.88OmerosN/AN/A-$156.82M-$2.65-1.27 SummaryOmeros beats Cumberland Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Cumberland Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPIX vs. The Competition Export to ExcelMetricCumberland PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.51M$2.73B$5.52B$9.41BDividend YieldN/A1.79%3.80%4.04%P/E Ratio-12.888.9428.0419.84Price / Sales1.27697.47429.5399.59Price / Cash14.42161.2635.8457.94Price / Book2.005.008.125.65Net Income-$6.48M$30.99M$3.25B$258.00M7 Day Performance7.33%1.69%0.97%2.09%1 Month Performance-39.93%9.20%7.36%11.13%1 Year Performance123.61%-1.25%31.31%18.40% Cumberland Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPIXCumberland Pharmaceuticals0.8866 of 5 stars$3.22-13.2%N/A+152.4%$55.51M$37.87M-12.8880Trending NewsOMEROmeros3.7837 of 5 stars$3.08-3.8%$18.00+484.4%-33.1%$187.50MN/A-1.16210Positive NewsAnalyst RevisionGap UpASMBAssembly Biosciences3.7919 of 5 stars$18.56+2.3%$33.00+77.8%+27.1%$138.55M$32.15M-2.98100Trending NewsLLYEli Lilly and Company4.979 of 5 stars$772.82-1.0%$1,011.61+30.9%-15.8%$739.87B$45.04B62.8847,000Trending NewsJNJJohnson & Johnson4.7823 of 5 stars$155.23-0.5%$170.88+10.1%+4.1%$375.37B$88.82B17.27138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionABBVAbbVie4.7838 of 5 stars$187.44-1.0%$211.29+12.7%+9.1%$334.34B$56.33B79.7655,000Trending NewsEx-DividendAnalyst RevisionMRKMerck & Co., Inc.4.9955 of 5 stars$80.890.0%$109.19+35.0%-35.2%$203.22B$64.17B11.7775,000Positive NewsPFEPfizer4.9618 of 5 stars$25.23-0.6%$28.55+13.2%-18.1%$144.29B$62.46B18.2881,000Trending NewsBMYBristol Myers Squibb4.8953 of 5 stars$46.50-0.9%$58.00+24.7%+11.4%$95.49B$47.64B17.4234,100Trending NewsAnalyst RevisionZTSZoetis4.9604 of 5 stars$156.98-1.4%$212.13+35.1%-17.6%$70.87B$9.26B28.1813,800Trending NewsAnalyst DowngradeAnalyst RevisionRPRXRoyalty Pharma4.9716 of 5 stars$35.59-2.1%$47.33+33.0%+26.2%$20.45B$2.26B19.2480News CoveragePositive NewsDividend Announcement Related Companies and Tools Related Companies OMER Alternatives ASMB Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives RPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPIX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
